Search results for "GLIOBLASTOMA"

showing 10 items of 137 documents

Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma

2018

Since the proper activation of T cells requires the physical interaction with target cells through the formation of immunological synapses (IS), an alteration at this level could be a reason why tumors escape the immune response. As part of their life cycle, it is thought that T cells alternate between a static phase, the IS, and a dynamic phase, the immunological kinapse (IK), depending on high or low antigen sensing. Our investigation performed in tissue samples of human glioma shows that T cells are able to establish synapsing interactions not only with glioma tumorigenic cells, but also with stromal myeloid cells. Particularly, the IS displaying a T cell receptor-rich (TCR-rich) central…

0301 basic medicineStromal cellCD3 ComplexImmunological SynapsesT-LymphocytesT cellAntigen-Presenting CellsImmunological synapse03 medical and health sciencesImaging Three-DimensionalImmune systemAntigenGliomaTumor MicroenvironmentmedicineHumansMyeloid CellsBrain NeoplasmsChemistryGliomaGeneral Medicinemedicine.diseaseImmunological SynapsesCell biology030104 developmental biologymedicine.anatomical_structureTechnical AdvanceTumor EscapeTumor EscapeGlioblastomaJCI Insight
researchProduct

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in gliobla…

2019

Abstract Background Targeted approaches for inhibiting epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases (RTKs) in glioblastoma (GBM) have led to therapeutic resistance and little clinical benefit, raising the need for the development of alternative strategies. Endogenous LRIG1 (Leucine-rich Repeats and ImmunoGlobulin-like domains protein 1) is an RTK inhibitory protein required for stem cell maintenance, and we previously demonstrated the soluble ectodomain of LRIG1 (sLRIG1) to potently inhibit GBM growth in vitro and in vivo. Methods Here, we generated a recombinant protein of the ectodomain of LRIG1 (sLRIG1) and determined its activity in various cellular GBM mo…

0301 basic medicinebiologyChemistryEGFRReceptor Protein-Tyrosine KinasesglioblastomaLRIG1AXLProximity ligation assayReceptor tyrosine kinase03 medical and health sciences030104 developmental biology0302 clinical medicineEctodomainDownregulation and upregulation030220 oncology & carcinogenesisBasic and Translational Investigationsbiology.proteinCancer researchreceptor tyrosine kinaseEpidermal growth factor receptorStem cellCell adhesionNeuro-oncology Advances
researchProduct

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

2018

Abstract Background: The Slit-Robo pathway has been shown to participate in the pathogenesis of several malignant diseases in addition to its physiologic role during the development of the central nervous system (CNS). However, the relevance of the Slit-Robo pathway in acute promyelocytic leukemia (APL) is presently unknown. We investigated the status of the Slit-Robo pathway in APL following the recent demonstration by Amodeo et al (CellRep. 2017) that the PML protein induces neural stem/progenitor cells migration by inhibiting the SLIT2 gene, which was associated with an increased presence of H3K27me3 in the SLIT2 promotor region. Moreover, sensitivity towards the PML-targeting drug arsen…

Acute promyelocytic leukemiaPrimary Glioblastomamedicine.medical_specialtyAcute leukemiaProliferation indexbusiness.industryImmunologyHealthy subjectsCell BiologyHematologymedicine.diseaseSlit2 proteinBiochemistryColony formationFamily medicinemedicinebusinessCell survivalBlood
researchProduct

Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors.

2000

In tumor tissue specimens of 27 primary and 17 secondary glioblastomas and the precursor lesions, the immunohistochemical expression patterns of the membrane protein CD44s, the basal lamina proteins laminin, collagen IV, and fibronectin, the lectin galectin-3 recognizing tenascin and N-CAM as well as of the matrix-degrading enzymes matrix metalloproteinase MMP-2 and MMP-9, and cathepsin D were studied. Besides expression of basal lamina proteins in vessels, all glioblastomas and the precursor lesions showed strong immunoreactivity of CD44s, tenascin, galectin-3, and N-CAM which were restricted to solid tumor masses. Present in solid tumor areas, MMP-2, MMP-9 and cathepsin D were also strong…

AdultCancer Researchanimal structuresGalectin 3TenascinCathepsin DBiologyAstrocytomaCathepsin DLamininGliomamedicineHumansCell adhesionNeural Cell Adhesion MoleculesBrain NeoplasmsMiddle Agedmedicine.diseaseMolecular biologyAntigens DifferentiationImmunohistochemistryMatrix MetalloproteinasesFibronectinsFibronectinmedicine.anatomical_structureHyaluronan ReceptorsMembrane proteinMatrix Metalloproteinase 9biology.proteinMatrix Metalloproteinase 2Basal laminaCollagenLamininNeoplasm Recurrence LocalGlioblastomaInvasionmetastasis
researchProduct

Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudores…

2017

Abstract Background Response Assessment in Neuro-Oncology Criteria (RANO), are used to asses response to first-line treatment of glioblastoma (GBM). Differentiation between response and pseudoresponse under treatment with Bevacizumab (BVZ) remains challenging. This study evaluates ADC changes in patients with radiographic pseudoresponse under treatment with (BVZ). Methods Patients (n = 40) with recurrent GBM under-treatment with BVZ underwent MRI before, two and four months after treatment with BVZ. In patients with radiological pseudoresponse (n = 11), ADC analyses were performed. Areas with decreasing T1 contrast enhancement (CE) and FLAIR signal decrease were manually selected and compar…

AdultMaleBevacizumabRadiographyPseudoresponseFluid-attenuated inversion recovery030218 nuclear medicine & medical imaging03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImage Interpretation Computer-AssistedmedicineHumansEffective diffusion coefficientRadiology Nuclear Medicine and imagingIn patientAgedRadiological and Ultrasound TechnologyBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseHyperintensityBevacizumabbody regionsDiffusion Magnetic Resonance ImagingTreatment OutcomeFemaleNeurology (clinical)Neoplasm Recurrence LocalGlioblastomabusinessNuclear medicine030217 neurology & neurosurgerymedicine.drugGlioblastomaJournal of Neuroradiology
researchProduct

Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.

2014

Glioblastoma (GBM) is the most frequent and malignant primary brain tumor. Conventional therapy of surgical removal, radiation and chemotherapy is largely palliative. Major vault protein (MVP), the main component of the vault organelle has been associated with multidrug resistance by reducing cellular accumulation of chemotherapeutic agents. With regard to cancer, MVP has been shown to be overexpressed in drug resistance development and malignant progression. The aim of the present study was to evaluate the MVP gene dosage levels in 113 archival samples from GBM and its correlation with patients' survival and epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog (PTEN) …

AdultMaleBiologyGene dosageStatistics NonparametricYoung AdultMajor vault proteinmedicinePTENTensinHumansEpidermal growth factor receptorMultiplex ligation-dependent probe amplificationAgedVault Ribonucleoprotein ParticlesPolysomyBrain NeoplasmsGeneral NeurosciencePTEN PhosphohydrolaseCancerMiddle Agedmedicine.diseaseErbB ReceptorsGene Expression Regulation NeoplasticMutationCancer researchbiology.proteinFemaleGlioblastomaChromosomes Human Pair 7Neuroscience
researchProduct

Resting-State Functional Connectome in Patients with Brain Tumors Before and After Surgical Resection

2020

Purpose: High-grade glioma surgery has evolved around the principal belief that a safe maximal tumor resection improves symptoms, quality of life, and survival. Mapping brain function has been recently improved by resting-state functional magnetic resonance imaging (rest-fMRI), a novel imaging technique that explores networks connectivity at “rest.” Methods: This prospective study analyzed 10 patients with high-grade glioma in whom rest-fMRI connectivity was assessed both in single-subject and in group analysis before and after surgery. Seed-based functional connectivity analysis was performed with CONN toolbox. Network identification focused on 8 major functional connectivity networks. A v…

AdultMaleBrain mappingFunctional connectivity03 medical and health sciences0302 clinical medicineSalience (neuroscience)Region of interestGliomaNeural PathwaysConnectomemedicineHumansFunctional disconnectionResting-state fMRIDefault mode networkAgedBrain MappingResting state fMRImedicine.diagnostic_testBrain Neoplasmsbusiness.industryBrainMiddle Agedmedicine.diseaseMagnetic Resonance ImagingBrain tumor030220 oncology & carcinogenesisQuality of LifeFemaleSurgeryNeurology (clinical)GlioblastomabusinessFunctional magnetic resonance imagingNeuroscience030217 neurology & neurosurgeryWorld Neurosurgery
researchProduct

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

2010

Abstract Purpose: Quantitative methylation-specific tests suggest that not all cells in a glioblastoma with detectable promoter methylation of the O6-methylguanine DNA methyltransferase (MGMT) gene carry a methylated MGMT allele. This observation may indicate cell subpopulations with distinct MGMT status, raising the question of the clinically relevant cutoff of MGMT methylation therapy. Epigenetic silencing of the MGMT gene by promoter methylation blunts repair of O6-methyl guanine and has been shown to be a predictive factor for benefit from alkylating agent therapy in glioblastoma. Experimental Design: Ten paired samples of glioblastoma and respective glioblastoma-derived spheres (GS), c…

AdultMaleCancer ResearchMethyltransferaseDNA repairBiologyDNA methyltransferaseGene dosageO(6)-Methylguanine-DNA MethyltransferaseGene FrequencyTumor Cells CulturedHumansPromoter Regions GeneticneoplasmsAgedAged 80 and overBrain NeoplasmsO-6-methylguanine-DNA methyltransferaseMethylationDNA MethylationMiddle AgedMolecular biologydigestive system diseasesChromatinOncologyCpG siteDNA methylationFemaleGlioblastomaClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.

1995

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is a main determinant of resistance of tumor cells to the cytostatic activity of chemotherapeutic alkylating agents (methylating and chloroethylating nitrosoureas) and is effective in protecting normal cells against genotoxic and carcinogenic effects resulting from DNA alkylation. Therefore, the level of expression of MGMT is significant for the response of both the tumor and the non-target tissue following application of nitrosoureas in tumor therapy. To determine the expression of MGMT in tumor tissue, we have assayed MGMT activity in 68 breast carcinomas and 38 brain tumors. There was a wide variation of MGMT expression…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyMethyltransferaseDNA RepairMammary glandBlotting WesternBreast NeoplasmsBiologyAstrocytomaO(6)-Methylguanine-DNA MethyltransferaseGliomaDNA Repair ProteinmedicineCarcinomaHumansneoplasmsCarcinogenAgedEpitheliomaL-Lactate DehydrogenaseBrain NeoplasmsAstrocytomaMethyltransferasesMiddle Agedmedicine.diseasedigestive system diseasesmedicine.anatomical_structureOncologyCancer researchFemaleGlioblastomaHeLa CellsInternational journal of cancer
researchProduct

Enhanced Interleukin-1β Release and Longevity of Glioma-associated Peripheral Blood Monocytes in Vitro

1994

Interleukin-1 (IL-1) plays a controversial role in the immune response. Besides its activation of immune cells and juvenile central nervous system cells, monocyte-derived IL-1 may be able to stimulate the malignant transformation and proliferation of glial brain tumor cells expressing IL-1 receptors. The aim of this study was to determine the growth pattern and the IL-1 beta release of long-term cultured peripheral blood monocytes of glioma patients. At 6- to 7-day intervals, the vital monocytes, characterized by CD14 immunophenotyping, were counted. By the use of a specific IL-1 beta enzyme-linked immunosorbent assay, the IL-1 beta content of monocyte culture supernatants derived from 13 s…

AdultMaleCell SurvivalCD14In Vitro TechniquesMonocytesImmune systemImmunophenotypingReference ValuesGliomaTumor Cells CulturedmedicineHumansAgedBrain Neoplasmsbusiness.industryMonocyteInterleukinMiddle AgedPrognosismedicine.diseaseCell Transformation Neoplasticmedicine.anatomical_structureCell cultureImmunologyFemaleSurgeryNeurology (clinical)Neoplasm Recurrence LocalGlioblastomabusinessCell DivisionInterleukin-1Blood samplingNeurosurgery
researchProduct